#NeuralCloud Achieves ISO 13485:2016 Certification
NeuralCloud Solutions Inc., a subsidiary of AI/ML Innovations Inc., has successfully obtained the ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP). This certification is a recognition of the company’s commitment to quality management standards in developing Software as a Medical Device (SaMD) for electrocardiogram (ECG) analysis.
The ISO 13485:2016 certification, awarded by TÜV USA, Inc., encompasses the entire quality management system of NeuralCloud. The scope includes design, development, production, and distribution of its ECG software products, which provide features such as PQRST waveform delineation, interval calculation, and arrhythmia analytics. This internationally recognized quality standard is pivotal for ensuring the reliability and safety of medical devices.
Achieving certification under the MDSAP is particularly significant for NeuralCloud as it demonstrates readiness to meet stringent regulatory requirements across multiple jurisdictions, including the United States, Canada, Australia, Brazil, and Japan. The MDSAP framework allows a single audit to satisfy the quality management system criteria of various regulatory authorities, streamlining the compliance process.
While this certification bolsters NeuralCloud’s position in the medical device market, it is essential to note that it does not constitute product clearance or marketing authorization. The company must still navigate further regulatory approvals and maintain compliance with applicable premarket reviews. NeuralCloud's executives emphasize that the quality management system is critical not only for regulatory acceptance but also for building trust with healthcare partners and stakeholders.
Esmat Naikyar, President of NeuralCloud, expressed that achieving this certification establishes a solid foundation for the company to operate as a regulated medical device entity. Paul Duffy, Executive Chairman and CEO of AIML, highlighted this milestone as pivotal in reinforcing the company’s strategy for engaging with regulators and clinical partners as it expands its medical device portfolio.
The ISO 13485:2016 certification signifies that NeuralCloud Solutions Inc. has established a quality management system compliant with international standards for medical devices. This certification aids in regulatory readiness but does not grant product clearance or marketing authorisation. It is relevant for organisations operating in multiple jurisdictions, such as Canada and the U.S. However, it does not replace necessary premarket reviews or inspections from regulatory authorities.
MDSAP allows NeuralCloud to undergo a single quality management system audit that satisfies the requirements of multiple regulatory authorities, such as the FDA in the U.S. and Health Canada. This reduces audit burdens and can streamline regulatory processes. However, while beneficial, MDSAP does not eliminate the need for regulatory inspections or product clearances required for market entry.
The MDSAP certification for NeuralCloud was issued by TÜV USA, Inc. This certification aids in aligning NeuralCloud's quality management practices with international regulations, but does not equate to a marketing authorisation for the company's products.
NeuralCloud’s ISO 13485:2016 certification applies to its Software as a Medical Device (SaMD) for ECG analysis, which includes advanced functionalities like arrhythmia analytics and signal quality scoring. However, it is important to note that the certification does not indicate that these products are currently cleared for sale or use in any market.
While MDSAP certification supports regulatory readiness and can help streamline audits, it does not provide product clearance for marketing or replace premarket review requirements. Additionally, regulatory authorities, including the FDA, may still conduct inspections when deemed necessary.
NeuralCloud's achievement of ISO 13485:2016 certification does establish a framework for quality management; however, there are inherent risks in the implementation of its products, including potential regulatory approvals and market conditions. Forward-looking statements highlight that uncertainties exist beyond NeuralCloud's control.
Achieving ISO certification enhances NeuralCloud’s ability to interact with regulators and clinical partners, potentially opening up new market opportunities for its ECG-focused technologies. Nevertheless, these opportunities depend on future regulatory approvals and market conditions, which present inherent uncertainties.
AI/ML Innovations Inc. trades on the Canadian Securities Exchange under the ticker symbol AIML, the OTCQB Venture Market with the ticker AIMLF, and the Frankfurt Stock Exchange as 42FB. The trading environment carries risks, including market volatility and regulatory pressures.